Rosetta Genomics Ltd. (ROSG) Appoints Dr. Maria Fe Paz As Interim Chief Medical Officer

PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Maria Fe Paz, M.D. Ph.D., effective immediately, as a medical affairs consultant in the role of Interim Chief Medical Officer, with plans to transition her to Chief Medical Officer of Rosetta Genomics upon receipt of a valid work visa that supports her planned relocation to the U.S.

Suggested Articles

A who’s who of Big Pharmas, including Pfizer, Johnson & Johnson and Merck, have banded together to bolster the development of new antibiotics.

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.